Navigation Links
Parker Waichman LLP Represents Pennsylvania Man in Lawsuit Alleging Actos Caused his Bladder Cancer
Date:6/7/2013

New York, New York (PRWEB) June 07, 2013

Parker Waichman LLP, a national law firm dedicated to protecting the victims of defective drugs, has filed a lawsuit on behalf of a Pennsylvania man who allegedly developed bladder cancer after taking the diabetes drug Actos (pioglitazone). The suit was filed on May 23rd in the U.S. District Court for the Western District of Louisiana (Case No. 6:13-cv-1170) as part of the multidistrict litigation entitled In Re: Actos (Pioglitazone) Products Liability Litigation (6:11-md-2299). Takeda Pharmaceuticals, America; Takeda Pharmaceuticals USA, Inc. f/k/a Takeda Pharmaceuticals North America, Inc.; Takeda Pharmaceutical Company Limited; and Eli Lilly and Company have been named as Defendants.

According to the Complaint, the Plaintiff started taking Actos in November 2003 to treat his Type 2 diabetes. By August 2006, he was diagnosed with bladder cancer. The suit alleges that Actos caused the bladder cancer due to its defective nature. Furthermore, the suit alleges that the Defendants knew about the risk of bladder cancer but failed to disclose this information to consumers in order to protect financial interests. The Plaintiff is alleging that Actos caused pain and suffering, emotional distress and economic damages in the form of medical expenses and lost wages. The suit is also seeking damages for loss of consortium on behalf of the Plaintiff’s spouse.

In June 2011, the U.S. Food and Drug Administration (FDA) warned that taking Actos for more than a year could significantly increase the risk of bladder cancer. The safety label on Actos was updated to address this risk*. Additional research supports the link between Actos and bladder cancer. Last May, a study in the British Medical Journal** found that Actos users were twice as likely to develop bladder cancer after two years. That July, the Canadian Medical Association Journal*** found that patients taking the medication were
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related medicine news :

1. Parker Waichman LLC Applauds Seniors for their Role in Helping to Recover $14.9 billion in Medicare Fraud over the Past Four Years
2. Parker Waichman LLP’s Jordan Chaikin Is Appointed to the Executive Committee of the Plaintiff’s Leadership Team in Emerson Electric Co. Wet/Dry Vac Litigation
3. Woman with Bilateral DePuy Pinnacle Hip Implant Alleges Metal Hips are Flawed in Lawsuit Filed by Parker Waichman LLP
4. Atlantic City Hotel’s Negligence Caused Conditions that Led to Serious Injuries, Alleges Lawsuit Filed by Parker Waichman LLP
5. Parker Waichman LLP Files Appeal over the Pennsylvania Department of Environmental Protection’s Ruling that Natural Gas Wells Did not Harm Couple's Drinking Water Supply
6. Parker Waichman LLP Designated as Co-Lead Counsel in the Consolidation of Hurricane Sandy-related Litigation Against the Long Island Power Authority and/or National Grid
7. Medtronic Infuse Lawsuit News: Parker Waichman LLP Alerts the Public to the June Release of Yale’s Infuse Bone Graft Study
8. Diabetes Drug Byetta Caused Arkansas Man’s Pancreatic Cancer and Resulting Injuries, Alleges Lawsuit Filed by Parker Waichman LLP and Co-Counsel
9. Mirena IUD Lawsuit Update: Supreme Court of New Jersey Centralizes Litigation; Parker Waichman LLP Underscores the Advantages of this Decision
10. DePuy Pinnacle Hip Implant Caused Elevated Ion Levels, Revision Surgery, Alleges Lawsuit Filed by Parker Waichman LLP
11. DePuy ASR Lawsuit Update: Parker Waichman LLP Commends Judge’s Refusal of Appeal for New Trial; DePuy Still Must Pay $8.3 Million Verdict
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... NC (PRWEB) May 04, 2015 ... provider created a stir and showed the healthcare ... a major healthcare procedure, the downside of balance ... of a healthcare provider billing a patient for ... chooses to reimburse and what the provider chooses ...
(Date:5/4/2015)... Gettysburg, Pennsylvania (PRWEB) May 04, 2015 ... bicycle and hand cycle ride in the last decade ... after riding 110 miles in two days from the ... national non-profit saw 581 registered disabled and able-bodied participants ... Face of America recognizes and honors the commitment and ...
(Date:5/4/2015)... Angeles, CA (PRWEB) May 04, 2015 ... Hinds, Eric Gladen’s documentary Trace Amounts, and Allison Folmar, ... annual autism conference held internationally. , On Sunday, May ... Is recovery from autism possible?" Are you interested in ... You’re In There: winning our war against autism ...
(Date:5/4/2015)... Today, Cireson reveals the following key ... to strengthen core service & asset management solutions ... consume Microsoft System Center and Cireson via Microsoft Azure ... Company transitioning from a direct sales presence to ... with expanding new solutions for password reset management, gamification, ...
(Date:5/3/2015)... (PRWEB) May 03, 2015 Women’s ... their Facebook page. , Their Facebook page ... many services the Practice has, it’s multiple locations, Providers ... Women’s Excellence has a very strong social media presence, ... and You Tube. , Women’s Excellence is the ...
Breaking Medicine News(10 mins):Health News:Out of Network Balance Billing Without Being Viewed as Fraud 2Health News:Out of Network Balance Billing Without Being Viewed as Fraud 3Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 2Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 3Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 4Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 2Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 3Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 4Health News:Cireson Unveils New Microsoft Cloud & System Center Strategy 2Health News:Cireson Unveils New Microsoft Cloud & System Center Strategy 3Health News:Cireson Unveils New Microsoft Cloud & System Center Strategy 4
... WASHINGTON, July 22 There are many provisions in ... care greatly about the freedom to choose their health care. Some of ... * Eliminates Existing Private Insurance Coverage (i.e., Eliminates Your Choice ... But Is Just Fine With You and Your Family) , ...
... , WASHINGTON, July 22 The ... Tobacco-Free Kids: , , The U.S. ... so-called electronic cigarettes by seeking to block importation of these products ... potential health risks of these products. The FDA announced today ...
... , PORTLAND, Ore., July 22 For ... originally created and produced videos developed for myRegence.com , a health ... The 30th Annual Telly Awards are widely considered to be ... from more than 14,000 entries worldwide. , , ...
... , , OWINGS MILLS, Md., July 22 ... MED ), our Directors, Employees and Associates are delighted that ... been nominated by President Obama, and confirmed by the U.S. Senate, as ... , Gen. McCarthy has served his country in ...
... SAN DIEGO, July 22 Orexigen Therapeutics, Inc. (Nasdaq: ... market and other conditions, 9,000,000 shares of its common stock in ... to grant to the underwriter a 30-day option to purchase up ... if any. All of the shares are being offered by Orexigen. ...
... , , MENLO PARK, Calif., July ... results for the second quarter ended July 3, 2009. , ... revenues increased 11% to $60,862,000, as compared to $54,956,000 in the second ... as compared to $50,801,000 in the second quarter of 2008. Net ...
Cached Medicine News:Health News:Mandate for Health Insurance: Inconvenient Truths About How It Will Affect You and Your Family 2Health News:FDA Acts to Protect Public Health from Electronic Cigarettes 2Health News:FDA Acts to Protect Public Health from Electronic Cigarettes 3Health News:Regence Wins Four Telly Awards for Health and Wellness Videos 2Health News:Medifast Independent Director Lt. Gen. Dennis McCarthy Confirmed as Assistant Secretary of Defense for Reserve Affairs 2Health News:Medifast Independent Director Lt. Gen. Dennis McCarthy Confirmed as Assistant Secretary of Defense for Reserve Affairs 3Health News:Orexigen(R) Therapeutics Announces Proposed Public Offering of Common Stock 2Health News:Exponent Reports Second Quarter 2009 Results 2Health News:Exponent Reports Second Quarter 2009 Results 3Health News:Exponent Reports Second Quarter 2009 Results 4Health News:Exponent Reports Second Quarter 2009 Results 5Health News:Exponent Reports Second Quarter 2009 Results 6Health News:Exponent Reports Second Quarter 2009 Results 7Health News:Exponent Reports Second Quarter 2009 Results 8Health News:Exponent Reports Second Quarter 2009 Results 9
(Date:5/4/2015)...  CytRx Corporation (Nasdaq: CYTR ), a ... today announced an interim analysis from its two ... with either gemcitabine or ifosfamide. Both studies combine ... doses of aldoxorubicin. The combinations appear to be ... level of aldoxorubicin (170 mg/m2), impressive tumor responses ...
(Date:5/4/2015)... May 4, 2015  Geneia, a company of ... solutions to improve healthcare efficiencies, today announced a ... Center (BNRC) use Geneia,s advanced analytics solution ... the quality and lower the cost of patient ... outcomes, claims and utilization data from multiple sources ...
(Date:5/4/2015)... INDIANAPOLIS , May 4, 2015 ... released two new reports that provide a comprehensive ... reports highlight how Lilly is evolving its approach ... and capabilities in partnership with others to have ... 2014 Corporate Responsibility Update offers a thorough ...
Breaking Medicine Technology:CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 2CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 3CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 4CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 5CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 6CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 7Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 2Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 3Lilly Releases Corporate Responsibility, Global Health Reports 2Lilly Releases Corporate Responsibility, Global Health Reports 3Lilly Releases Corporate Responsibility, Global Health Reports 4
... , , BERLIN ... NKTR ) presented favorable data today on lead oncology program, ... investigational compound in ovarian cancer. These data were presented at ... Oncology (ESMO) 2009 Joint Multidisciplinary Congress in Berlin, Germany. , ...
... , , , ... a Phase II trial of regorafenib (BAY 73-4506), a potent oral multi-kinase ... partial response rate and 50 percent stabilization rate in patients with metastatic ... at the joint 15th Congress of the European CanCer Organisation and 34th ...
Cached Medicine Technology:NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 2NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 3NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 4NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 5Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 2Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 3Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 4
Rounded tip spatula with 20 gauge shaft. Black finish for reduced glare....
Triangular 0.5 mm angled tip with 4 mm flat surface. Round knurled handle with dull finish. Tip angle: 110o. Most popular size or model....
10 mm angled tip with indentation on side and gently curved blade. Round knurled handle with polished finish. Indentation: left side....
0.5 mm x 15 mm angled round blade with smoothly pointed tip and gently curved blade. Round knurled handle with polished finish....
Medicine Products: